Satellos Bioscience Inc.

BASECAMP Study

The BASECAMP study is a global, randomized, placebo-controlled Phase 2 clinical trial for three months, followed by a long-term, cross-over extension for an additional nine months (i.e., 12 months in total) – all in ambulatory boys with DMD.

The BASECAMP study is designed to evaluate SAT-3247 in 51 ambulatory boys with DMD aged 7, 8 or 9 years. Primary endpoints include safety, tolerability and dynamometry. Secondary endpoints will assess SAT-3247’s impact on muscle quality, function and regeneration. The BASECAMP trial is actively enrolling at clinical centers in the United States, Canada, Belgium, Poland, Spain, Serbia, the United Kingdom and Australia. The three-month placebo portion of BASECAMP is randomized 1:1:1 into one of three groups: placebo or one of a 60 mg or 120 mg dose of SAT-3247 on a weekday regimen. In the long-term cross-over, placebo participants will be randomized 1:1 to one of two dose levels.

Active and planned clinical sites have identified a pool of potential participants exceeding the number required to support planned screening and enrollment activities in the coming months. The company expects to report clinical data from the study in the fourth quarter of 2026.

Please refer to the section “Regulatory Process” in the Company’s AIF for further details on the clinical drug development process.